Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors Clinical Trial

Official title:

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04980690
• Other study ID #: IBC0966-I/IIa
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: August 31, 2021
• Est. completion date: December 2025

Study information

• Verified date: March 2023
• Source: SUNHO(China)BioPharmaceutical CO., Ltd.
• Contact: tie xu
• Phone: 18036618680
• Email: 18036618680[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I/IIa study to evaluate the safety, tolerability and efficacy of IBC0966 for the treatment of subjects with advanced malignant tumors.

Description:

The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa).

First, the Phase Ia dose escalation will be carried out. After switching to the 3+3 escalation mode, the Phase Ib dose extension study can be carried out at the same time. After Phase Ia is completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 228
• Est. completion date: December 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Aged 18 to 75 years old male and female.

2. Phase I (including phase Ia and phase Ib) will enroll patients with advanced malignant tumors who have failed standard treatments.

3. Phase IIa Study-Group A: Recurrent or metastatic triple-negative breast cancer diagnosed by histopathology that has failed standard treatments. Triple-negative breast cancer is defined as estrogen receptor (ER), progesterone receptor (PR), and human epidermis Growth factor receptors (HER2) are all negative.

4. Phase IIa Study-Group B: Advanced/metastatic non-small cell lung cancer with no driver gene mutations that has failed standard treatment confirmed by histopathology.

5. Phase IIa Study-Group C: Recurrent or metastatic head and neck squamous cell carcinoma that failed standard treatments confirmed by histopathology: including nasopharyngeal carcinoma and non-nasopharyngeal head and neck squamous cell carcinoma.

6. Phase IIa study-Group D: Recurrent or metastatic peripheral T-cell lymphoma (PTCL) diagnosed by histopathology that failed standard treatment: Including non-specific PTCL, NK/T-cell lymphoma (nasal type), and angioimmunoblast Cellular T cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), subcutaneous panniculitis-like T cell lymphoma, enteropathic T cell lymphoma (EATL), and hepatosplenic T cell lymphoma (HSTL) Wait.

7. According to RECIST 1.1 or Lugano 2014 standards, there is at least one measurable lesion, and the measurable lesion has not received local treatment (including local radiotherapy, ablation, and interventional therapy).

8. Agree to provide previously stored tumor tissue specimens or perform a biopsy to collect tumor lesion tissue and send it to the central laboratory for PD-L1 expression level detection and TMB detection.

9. ECOG performance status 0-2.

10. Laboratory examination should meet: ? Blood routine: hemoglobin (HGB) =100 g/L, white blood cell count (WBC) =3.0×10^9/L, neutrophil count (ANC) =1.5×10^9/L, platelet count ( PLT) =75×10^9/L; ?Blood biochemistry: total bilirubin (TBIL) =1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3.0×ULN, serum creatinine ( Cr)=1.5×ULN or calculate the creatinine clearance =50 mL/min according to the Cockcroft-Gault formula method.

11. Left ventricular ejection fraction (LVEF) = 50% by echocardiography.

12. Life expectancy =3 months.

13. Agree to use at least one medically approved contraceptive method during the trial period and at least 6 months after the last dose (female patients: such as intrauterine devices, contraceptives or condoms, etc.; male patients: such as condoms, abstinence, etc.). Female patients must be non-lactating.

14. Subjects must be fully informed of the content, process and possible risks and benefits of the research and sign the informed consent form. Good compliance, able to complete the study and follow-up.

Exclusion Criteria:

1. Known to have severe hypersensitivity to any monoclonal antibody (=CTCAE grade 3).

2. Not recovered from the adverse reactions caused by previous anti-tumor treatments (=CTCAE grade 1), excluding hair loss, pigmentation, and fatigue.

3. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.

4. Received any live vaccines within 4 weeks before enrollment.

5. Have undergone surgery within 4 weeks before enrollment, and the investigator believes that the patient's state has not recovered to the point where the study can be started.

6. Have a history of hemolytic disease, immune-mediated thrombocytopenia, or Evans syndrome within 3 months before enrollment. Currently suffering from active or suspicious autoimmune disease or a history of autoimmune disease within the past 2 years.

7. Phase Ia and Ib: previous exposure to any CD47 antibody, SIRPa antibody or CD47/SIRPa recombinant protein, or previous exposure to any anti-programmed death receptor 1 (PD-1) or anti-programmed death ligand 1 ( PD-L1) antibody.

8. Received any systemic anti-tumor therapy within 4 weeks before enrollment.

9. Participated in other clinical trials within 4 weeks before enrollment and used clinical investigational drugs during this period.

10. Central nervous system metastases with clinical symptoms were found within 4 weeks before enrollment. Patients who have previously received treatment for brain or meningeal metastases, if clinical stability has been maintained for at least 2 months, and have stopped systemic hormone therapy (dose>10 mg/day prednisone or other curative hormones) for more than 4 weeks can be included.

11. Patients with ascites (ascites), pleural effusion (pleural effusion) or pericardial effusion that cannot be controlled by drainage or other methods.

12. Past or present suffering from other malignant tumors (except for cured skin basal cell carcinoma and cervical carcinoma in situ).

13. Suffering from serious or poorly controlled diseases, including but not limited to: ? Myocardial infarction, arrhythmia, congestive heart failure, etc. that require treatment or intervention occurred within 3 months before enrollment. ?Human immunodeficiency virus (HIV) infection (HIV antibody positive); hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) positive and HBV DNA =500 IU/mL or =1×10^3 copies/mL) ; HCV antibody positive and HCV RNA positive. ? Poorly controlled diabetes, hypertension, thyroid disease, etc.; ?Severe and uncontrollable lung diseases (severe infectious pneumonia, interstitial lung disease, etc.) (=CTCAE grade 3); ?Uncontrolled serious Infection (=CTCAE grade 3).

14. With any situations that the researcher considers inappropriate to participate in this research.

Related Conditions & MeSH terms

• Advanced Malignant Tumors
• Neoplasms

Intervention

Biological:
• IBC0966
IBC0966 is an investigational product.

Locations

Country	Name	City	State
China	The Affiliated Tumor Hospital of Harbin Medical University	Harbin	Heilongjiang

Sponsors (1)

Lead Sponsor	Collaborator
SUNHO(China)BioPharmaceutical CO., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of adverse events (AEs) and SAEs (Phase ?)	To investigate the safety characteristics.	3 months after end event visit
Primary	Dose limiting toxicities (DLTs) (Phase ?)	To determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D).	28 days after first dose
Primary	Objective response rate (ORR) in dose expansion (Phase ?a)	To explore the clinical effectiveness. Tumor response based on RECIST 1.1 or Lugano 2014.	Baseline through up to 2 years or until disease progression
Secondary	Pharmacokinetic (PK) Cmax (Phase ?)	PK parameters (Cmax) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Pharmacokinetic (PK) Tmax (Phase ?)	PK parameters (Tmax) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Pharmacokinetic (PK) AUC 0-t (Phase ?)	PK parameters (AUC 0-t ) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Pharmacokinetic (PK) AUC 0-8 (Phase ?)	PK parameters (AUC 0-8) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Pharmacokinetic (PK) t1/2 (Phase ?)	PK parameters (t1/2) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Pharmacokinetic (PK) ?z (Phase ?)	PK parameters (?z) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Pharmacokinetic (PK) Css,max (Phase ?)	PK parameters (Css,max) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Pharmacokinetic (PK) Css,min (Phase ?)	PK parameters (Css,min) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Pharmacokinetic (PK) AUCss (Phase ?)	PK parameters (AUCss) following single dose.	Day1,2,3,7,14,21, 28 of DLT observation period , Day1of each subsequent cycle (each cycle is 7 days), and at the End of Treatment visit, up to about 2 years
Secondary	Objective response rate (ORR) in dose escalation (Phase ?)	Tumor response based on RECIST 1.1 or Lugano 2014.	Baseline through up to 2 years or until disease progression
Secondary	Incidence of adverse events (AEs) and SAEs (Phase ?)	To investigate the safety characteristics.	3 months after end event visit
Secondary	Immunogenicity of IBC0966 (Phase ?)	The frequency of anti-drug antibodies (ADA) against IBC0966.(Phase ?)	3 months after end event visit
Secondary	Progression free survival (PFS) (Phase ?a)	PFS as assessed using RECIST 1.1 or Lugano 2014.	Baseline through up to 2 years or until disease progression
Secondary	Overall survival (OS) (Phase ?a)	OS as assessed using RECIST 1.1 or Lugano 2014.	Baseline through up to 2 years or until disease progression
Secondary	Disease control rate (DCR) (Phase ?a)	DCR as assessed using RECIST 1.1 or Lugano 2014.	Baseline through up to 2 years or until disease progression
Secondary	Incidence of adverse events (AEs) and SAEs (Phase ?a)	To investigate the safety characteristics.	3 months after end event visit
Secondary	Immunogenicity of IBC0966 (Phase ?a)	The frequency of anti-drug antibodies (ADA) against IBC0966.(Phase ?a)	3 months after end event visit